(CNN) – “The antibodies in Evusheld, the only therapy available to protect people with reduced immune function against Covid-19, may lose their punch against the BA.4.6 subvariant, a new study shows.
BA.4.6 is an offshoot of the BA.4 subvariant of the Omicron coronavirus variant. Only a couple of mutations separate it from its predecessor, but it is slowly gaining ground in the United States, even against BA.5, which continues to dominate transmission.”
Each new variant seems to have a new worrisome mutation from the last, and BA.4 is no different. “In new tests, Dr. David Ho, a professor of microbiology and immunology at Columbia University, found that although this subvariant doesn’t seem to bind to our cells more easily than others, it does appear to evade the ability of some antibodies to neutralize it, including those in Evusheld.”
Click the link below to read more:
0 Comments